AIM Share Price | AIM ImmunoTech, Inc. Stock Analysis & Recommendation

Q: How big is AIM ImmunoTech, Inc.?

Market Cap: As of Jun 18, AIM ImmunoTech, Inc. has a market capitalization of 7.76 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, AIM ImmunoTech, Inc. reported net sales of 0.15 million and a net profit of -15.22 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of -1.32 million and total assets of 51.49 million.

Q: What does AIM ImmunoTech, Inc. do?

Overview:AIM ImmunoTech, Inc. is a specialty pharmaceutical company engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based chronic disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 7.76 Million (Micro Cap) Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 1,694.08% Debt Equity: 0.02 Return on Equity: 373.68% Price to Book: -2.01 Contact Details:Address: 2117 SW Highway 484, OCALA FL: 34473-7949 Tel: ['1 352 4487797', '1 888 5576480'] Fax: 1 352 4804620 Website: https://aimimmuno.com/

Q: Is AIM ImmunoTech, Inc. technically bullish or bearish?

As of 17 July 2025, the technical trend for AIM ImmunoTech, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a monthly MACD that is mildly bullish and a monthly RSI that is bullish. However, the weekly MACD and KST are bearish, indicating some weakness in the shorter term. The daily moving averages are bearish, which adds to the mixed signals. The Bollinger Bands show a mildly bearish stance on both weekly and monthly time frames. In terms of performance, AIM ImmunoTech has significantly underperformed against the S&P 500 over the longer term, with a year-to-date return of -86.82% compared to the S&P 500's 12.22%, and a one-year return of -91.25% versus 17.14% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

126.28 k

Shareholding (Sep 2025)

FII

0.05%

Held by 7 FIIs

DII

98.34%

Held by 2 DIIs

Promoter

0.00%

How big is AIM ImmunoTech, Inc.?

22-Jun-2025

As of Jun 18, AIM ImmunoTech, Inc. has a market capitalization of 7.76 million, categorizing it as a Micro Cap company, with net sales of 0.15 million and a net profit of -15.22 million over the latest four quarters.

View full answer

What does AIM ImmunoTech, Inc. do?

22-Jun-2025

AIM ImmunoTech, Inc. is a micro-cap specialty pharmaceutical company focused on developing immune-enhancing therapies for viral and immune-related disorders. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $7.76 million.

View full answer

Who are in the management team of AIM ImmunoTech, Inc.?

22-Jun-2025

As of March 2022, the management team of AIM ImmunoTech, Inc. includes Dr. William Mitchell as Chairman of the Board, Mr. Thomas Equels as Executive Vice Chairman, CEO, President, Secretary, and General Counsel, and Mr. Stewart Appelrouth as a Director.

View full answer

Is AIM ImmunoTech, Inc. technically bullish or bearish?

20-Sep-2025

As of July 17, 2025, AIM ImmunoTech's trend is mildly bullish with mixed signals from technical indicators, while it has significantly underperformed the S&P 500 with year-to-date and one-year returns of -86.82% and -91.25%, respectively.

View full answer

Compare AIM ImmunoTech, Inc. with Similar Stocks

Genprex, Inc.Context Therapeutics, Inc.KALA BIO, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 3 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

4,157.72%

Debt Equity

0.05

Return on Equity

258.70%

Price to Book

-0.52

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-31.67%

6 Months

-58.95%

1 Year

-92.57%

2 Years

-97.39%

3 Years

-97.9%

4 Years

-98.59%

5 Years

-99.53%

AIM ImmunoTech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.65%

EBIT Growth (5y)

-5.31%

EBIT to Interest (avg)

-20.43

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.02

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.59%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.47

EV to EBIT

-0.32

EV to EBITDA

-0.33

EV to Capital Employed

-1.43

EV to Sales

5.60

PEG Ratio

Dividend Yield

2320.50%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (1.61%)

Foreign Institutions

Held by 7 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 10.81% vs 52.56% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-4.40",
          "chgp": "47.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-3.70",
          "chgp": "10.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-90,961.50%",
          "val2": "-128,257.10%",
          "chgp": "3,729.56%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 40.34% vs -49.48% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.50",
          "val2": "-31.70",
          "chgp": "38.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.30",
          "val2": "-29.00",
          "chgp": "40.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-116,023.50%",
          "val2": "-157,930.70%",
          "chgp": "4,190.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.30

-4.40

47.73%

Interest

0.10

0.20

-50.00%

Exceptional Items

0.60

0.00

Consolidate Net Profit

-3.30

-3.70

10.81%

Operating Profit Margin (Excl OI)

-90,961.50%

-128,257.10%

3,729.56%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 10.81% vs 52.56% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-19.50

-31.70

38.49%

Interest

0.60

0.00

Exceptional Items

-0.50

-0.00

Consolidate Net Profit

-17.30

-29.00

40.34%

Operating Profit Margin (Excl OI)

-116,023.50%

-157,930.70%

4,190.72%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 40.34% vs -49.48% in Dec 2023

All Annual Results

Company CV

About AIM ImmunoTech, Inc.

AIM ImmunoTech, Inc.

Pharmaceuticals & Biotechnology

AIM ImmunoTech Inc., formerly Hemispherx Biopharma, Inc., is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Company Coordinates

Company Details

2117 SW Highway 484 , OCALA FL : 34473-7949

Tel: 1 352 44877971 888 5576480

https://aimimmuno.com/

Registrar Details

AIM ImmunoTech, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is AIM ImmunoTech, Inc.?

Watch in Real-Time

What does AIM ImmunoTech, Inc. do?

Who are in the management team of AIM ImmunoTech, Inc.?

Is AIM ImmunoTech, Inc. technically bullish or bearish?

Compare AIM ImmunoTech, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About AIM ImmunoTech, Inc.

Company Coordinates